📄 pharmacology and therapeutics

Same Result, Different Price: Compounded versus Branded Tirzepatide

This study demonstrates that compounded and branded tirzepatide yield statistically equivalent six-month weight loss outcomes, indicating that the decision between them hinges entirely on whether a patient's specific access to branded pricing (such as high retail or direct-pay costs versus low insurance copays) makes the compounded alternative a cost-saving option.

Original authors: Erly, B., Raja, S.

Published 2026-07-16

📖 6 min read🧠 Deep dive

CC BY 4.0

Original authors: Erly, B., Raja, S.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine you are standing in a massive, bustling marketplace where people are trying to buy a very special, powerful tool to help them lose weight. This tool is a medication called tirzepatide. For a long time, there was only one version of this tool available: a famous, brand-name version sold in big, shiny boxes. But recently, a new kind of shop opened up that sells a "homemade" or "compounded" version of the same tool. The big question everyone is asking is: "Is the homemade version just as good as the famous one, and is it actually cheaper?"

To understand this, you need to know two things. First, "effectiveness" just means: does the tool actually do the job? In this case, does it help people lose the same amount of weight? Second, "price" isn't just one number. In the real world, the price of the famous brand-name tool changes wildly depending on who you are. If you have a special insurance card, it might cost you just a tiny fee. If you pay cash without insurance, it might cost a fortune. If you buy it directly from the maker's website, it's somewhere in the middle. This paper is like a detective story that tries to figure out if the homemade tool works just as well as the famous one, and then asks the real question: "For your specific wallet, which one is actually the better deal?"

The Great Weight-Loss Showdown: Brand Name vs. The "Homemade" Version

So, here is the story. A team of researchers, led by Dr. Brian Erly and Shanmugesh Raja, decided to settle the debate once and for all. They looked at a huge group of real people—over 7,000 of them—who were using tirzepatide through a telehealth program called Mochi Health. Some of these people were using the famous brand-name versions (Mounjaro or Zepbound), and others were using the compounded versions.

The researchers were smart about how they compared them. They knew that people who could afford the brand-name drug might be different from those who couldn't (maybe they had better insurance or were starting at a different weight). So, they used a statistical trick called "propensity-score matching." Think of this like a matchmaking service for a dance. They took a person using the brand-name drug and found a partner using the compounded drug who looked almost exactly the same on paper: same age, same starting weight, same health conditions, and same insurance situation. They paired them up 718 times to make sure they were comparing apples to apples, not apples to oranges.

The Big Result: They Work the Same
When they checked the results after six months, the answer was surprisingly simple: The two versions worked exactly the same.

People using the brand-name drug lost an average of 11.4% of their body weight.
People using the compounded drug lost an average of 11.4% of their body weight.

The difference was so tiny (less than one-tenth of a percent) that it was statistically meaningless. The researchers even set a rule beforehand: if the difference was within 2 percentage points, they would call them "equivalent." They were well within that limit. So, if you are worried that the "homemade" version is weaker or less effective, this study says you don't need to worry. In terms of shedding pounds, they are twins.

The Twist: The Price Tag is a Trap
Since the effectiveness is the same, the only thing left to decide is the price. But here is where the story gets tricky. The paper argues that most people are asking the wrong question. They usually say, "The brand-name costs $1,200 a month, and the compounded one costs $200, so I save $1,000!"

The researchers say, "Wait a minute! That's not the whole story." The price of the brand-name drug isn't just one number; it's a sliding scale based on how you get it. They broke it down into five different scenarios to see who actually saves money:

The "Cash Only" Scenario: If you have no insurance and no special deals, the brand-name drug costs about $1,200 a month. In this case, the compounded version (at $200 a month) saves you a massive $6,000 over six months. This is the "strong case" where the homemade version is a total winner.
The "Direct from Maker" Scenario: The drug maker (Lilly) started selling directly to people without insurance for $299 to $449 a month. If you can get this deal, the compounded version still saves you money, but the savings shrink. You might save $594 or $1,494 over six months. It's still a win, but not a huge one.
The "Insurance Copay" Scenario: This is where the plot twists. If you have insurance that covers the drug, your monthly cost might be as low as $25 or $150.
- If your copay is $150, the brand-name drug costs $900 for six months, while the compounded version costs $1,200. Suddenly, the "cheap" compounded version is actually $300 more expensive than the brand!
- If your copay is $25, the brand-name drug is a steal at $150 for six months, making the compounded version $1,050 more expensive.

The Bottom Line
The paper concludes that the choice between the two isn't about which one works better—they both work the same. The choice is purely about your wallet and your specific situation.

If you are paying the full, high price for the brand-name drug (like the $1,200 list price), the compounded version is a fantastic, money-saving alternative.
If you have insurance that gives you a low copay (under $200 a month), the brand-name drug is actually the cheaper option.

The researchers are careful to say they didn't prove the drugs are chemically identical in a lab (that's a different test), but in the real world, for the people they studied, the results were the same. They also noted that for some people, the real choice isn't "Brand vs. Compounded," but "Compounded vs. Nothing at all," because if the brand-name drug is too expensive, many people just stop taking the medicine entirely.

So, before you decide which version to buy, you have to look at your own price tag. If you are paying full retail, the compounded version is a great deal. If you have a low insurance copay, stick with the brand. It's not about which drug is stronger; it's about which price tag fits your pocket.

Technical Summary: Compounded versus Branded Tirzepatide

Problem Statement
The economic argument for compounded tirzepatide is traditionally constructed by comparing a single compounded price (typically $200–$ 400/month) against the branded retail list price ( $1,000–$ 1,200/month). This framing is identified as flawed because it ignores the actual price tiers accessible to patients. Branded tirzepatide (Mounjaro/Zepbound) is sold at sharply different price points depending on the patient's access pathway: insurance copays (often $25–$ 150/month), LillyDirect Self-Pay ( $299–$ 449/month), and retail cash prices. Consequently, the cost-saving claim for compounded formulations is conditional; it may hold for uninsured patients but collapses or reverses for those with low copays or access to manufacturer-direct programs. Furthermore, real-world comparisons often show branded formulations outperforming compounded ones, but these differences may reflect selection bias (e.g., insured patients having better adherence or baseline characteristics) rather than true pharmacological superiority.

Methodology
The authors conducted a retrospective cohort study using electronic health record and pharmacy data from Mochi Health, a U.S. telehealth obesity program.

Cohort: The study analyzed 7,271 patients with documented six-month weight observations, comprising 869 branded-only users and 6,402 compounded-only users. Switchers were excluded to avoid confounding.
Outcomes: The primary outcome was the mean percent body weight loss at six months. The secondary outcome was the response rate (≥10% weight loss).
Causal Inference: To address selection bias, the authors employed 1:1 nearest-neighbor propensity-score matching (PSM) with a 0.25 SD caliper. The propensity model included baseline covariates only: age, sex, baseline BMI, baseline weight, comorbid diabetes, hypertension, dyslipidemia, prior bariatric surgery, and self-reported insurance coverage. Post-treatment variables (e.g., adherence, time in program) were deliberately excluded to avoid over-adjustment bias.
Equivalence Testing: Unlike standard difference tests, the study pre-specified an equivalence margin of ±2 percentage points (pp) on mean weight loss. Equivalence was tested using two one-sided tests (TOST).
Causal Diagram: A Directed Acyclic Graph (DAG) was constructed to explicitly identify confounders and mediators. The DAG highlighted metformin use as a potential unmeasured confounder (acting as both a confounder for diabetes and a mediator for weight loss) that could not be reliably separated in the data.
Cost Analysis: The study performed a cost-minimization analysis (assuming equivalent effectiveness) across five branded price scenarios: Retail List Price, LillyDirect Maintenance Dose, LillyDirect Low Dose, Typical Insurance Copay, and Low Insurance Copay.

Key Results

Effectiveness: Before adjustment, branded users showed a marginal advantage in weight loss (11.71% vs. 11.51%). However, after PSM, the groups were balanced on all covariates (Standardized Mean Differences < 0.04), including insurance coverage. The matched mean weight loss was 11.44% for branded and 11.37% for compounded (difference +0.08 pp, 95% CI −0.70 to +0.80). The TOST confirmed statistical equivalence within the ±2 pp margin (p < 0.001). Similarly, the ≥10% response rates were statistically equivalent (59.3% vs. 57.2%).
Cost Comparison: The cost advantage of compounded tirzepatide is entirely dependent on the branded price tier the patient faces:
- Retail List Price: Compounded saves ~$6,000 over six months.
- LillyDirect Self-Pay (Maintenance): Compounded saves ~$1,494.
- LillyDirect Self-Pay (Low Dose): Compounded saves ~$594.
- Typical Insurance Copay ($150/mo): Compounded costs ~$300 more than branded.
- Low Insurance Copay ($25/mo): Compounded costs ~$1,050 more than branded.
Additives: The study explicitly did not analyze weight-loss enhancement from additives (e.g., B12, pyridoxine) due to sub-therapeutic dosing and lack of mechanism. However, it notes that additives may offer tolerability benefits (e.g., antiemetic effects of pyridoxine) and that compounded formulations allow for individualized tailoring not possible with branded SKUs.

Significance and Claims
The paper claims two primary contributions:

Effectiveness Equivalence: It provides evidence that, after adjusting for selection bias (specifically insurance status), compounded and branded tirzepatide produce statistically equivalent six-month weight loss outcomes within a clinically relevant margin. This suggests the observed "branded advantage" in unadjusted data is driven by patient selection rather than drug efficacy.
Conditional Cost Analysis: It reframes the cost debate from a static comparison to a conditional one. The paper argues that the "cost savings" narrative is only valid for patients facing high retail or self-pay prices. For patients with low insurance copays or access to manufacturer-direct programs, compounded tirzepatide is often the more expensive option with no detected effectiveness benefit.

The authors conclude that the choice between formulations is essentially a cost decision contingent on the patient's specific access tier. They emphasize that while compounded tirzepatide offers a critical access pathway for the uninsured or underinsured (who otherwise might receive no GLP-1 therapy), it is not a universally lower-cost substitute. The study explicitly disclaims claims of pharmacologic bioequivalence or safety equivalence, noting that residual confounding (e.g., unmeasured socioeconomic status) and the lack of pharmacy-level identifiers prevent broader generalizations about all compounded preparations.

The Great Weight-Loss Showdown: Brand Name vs. The "Homemade" Version

Technical Summary: Compounded versus Branded Tirzepatide

More like this